IP Library Granted Patent US 6,887,906
Granted Patent B1
US 6,887,906 · App. 09/108,673 · Granted May 3, 2005

Compositions and methods for the delivery of oligonucleotides via the alimentary canal

Assignee: ISISPharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,887,906
App. No.
09/108,673
Granted
May 3, 2005
Kind
B1
Abstract

The present invention relates to compositions and methods which enhance the transport of nucleic acids, especially oligonucleotides at various sites in the alimentary canal of an animal. The methods and compositions enhance the transport of oligonucleotides across the mucosa of the alimentary canal via the use of one or more penetration enhancers. The invention features the use of various fatty acids, bile salts, chelating agents and other penetration enhancers, as well as carrier compounds, to enhance the stability of nucleic acids and/or their transport across and/or into cells of the alimentary canal. In one preferred embodiment, the compositions and methods of the invention are utilized to effect the oral delivery of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic or prophylactic purposes.

Claims (4)

1. A composition comprising a nucleic acid and capric acid and lauric acid, or a nucleic acid and pharmaceutically acceptable salts of capric acid and lauric acid, wherein said nucleic acid has a modified nucleobase or a modified sugar residue.

2. The composition of claim 1 wherein said nucleic acid is an antisense oligonucleotide.

3. The composition of claim 2 wherein said antisense oligonucleotide decreases the expression of a cellular adhesion protein or the rate of cellular proliferation.

4. The composition of claim 1 wherein said nucleic acid has a cytosine to 5-methyl-cytosine substitution or a 2′-methoxyethoxy modification.

Assignments (2)
CHANGE OF NAME Recorded Jul 26, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043341/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 1998
From: TENG, CHING-LEOU; HARDEE, GREG
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 009620/0012 →
Continuity (1)
Continuation In Part 0888682900 · Jul 1, 1997